Search
for

    Glossary BRAVE-AA2

    clinical trial evaluating baricitinib for severe alopecia areata

    BRAVE-AA2 is a clinical trial designed to evaluate the efficacy and safety of a drug called baricitinib for treating alopecia areata, an autoimmune condition that causes hair loss. The trial specifically focuses on adults with severe alopecia areata and aims to determine how well the drug can help regrow hair and improve patients' quality of life.

    Related Terms

    Research 10 of 1000+

    1. Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies Journal of the American Academy of Dermatology · 2024 · 2 citations
    2. Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2 SKIN The Journal of Cutaneous Medicine · 2025
    3. Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2 Annales de dermatologie et de vénéréologie, FMC · 2023
    4. Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2 Skin · 2023
    5. Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials JEADV Clinical Practice · 2024
    6. 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2 Journal of The American Academy of Dermatology · 2023
    7. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2) American Journal of Clinical Dermatology · 2023 · 20 citations
    8. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    9. 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2 Journal of The American Academy of Dermatology · 2022 · 4 citations
    10. 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2 Journal of the American Academy of Dermatology · 2023 · 1 citations
    All research results →

    Learn 1

    1. Baricitinib JAK inhibitor pill used for severe alopecia areata

    Community 1

    1. How to deal with feeling ugly while balding but not brave enough to shave Reddit · 7 Apr 2026